1.Acute isoniazid poisoning in childhood.
Ji Tae CHOUNG ; Jun Tae PARK ; Jee Kyu LEE ; Kyu Eun LEE
Journal of the Korean Pediatric Society 1982;25(9):959-962
No abstract available.
Isoniazid*
;
Poisoning*
2.A Case of Isoniazid Induced Gynecomastia.
Min Kyung LEE ; Dong Jib NA ; Ho Seok JEON ; Yang Deok LEE ; Yong Seon CHO ; Min Soo HAN ; Hee Jeong YOON
Tuberculosis and Respiratory Diseases 2009;66(1):33-36
No abstract available.
Gynecomastia
;
Isoniazid
;
Male
3.Bitemporal Hemianopia Associated with Anti-Tuberculosis Medication.
Kyungmi OH ; Jae Hong JANG ; Byung Jo KIM ; Kun Woo PARK ; Dae Hie LEE
Journal of the Korean Neurological Association 2007;25(2):281-282
No abstract available.
Hemianopsia*
;
Isoniazid
;
Tuberculosis
4.Plasma concentration of rifampicin, isoniazid and pyrazinamide in pulmonary tuberculosis and pleural tuberculosis patients
Journal of Medical Research 2008;59(6):104-110
Background: Rifampicin, isoniazid, and pyrazinamide are oral essential anti-tuberculosis drugs on single or combined preparations. Worldwide research has shown that the plasma concentration of anti-tuberculosis drugs with daily therapeutic doses were seen significant lower than permitted in tuberculosis patients, especially for rifampicin and isoniazid. Objective: To investigate plasma concentration of rifampicin, isoniazid, and pyrazinamide in pulmonary tuberculosis and pleural tuberculosis patients. Methods: Determine plasma concentration of rifampicin, isoniazid, and pyrazinamide at 2 hours after administration in 168 tuberculosis patients by the HPLC method. Identify prevalence of low plasma concentrations of anti-tuberculosis drugs. Results: There was a wide range of plasma concentration of rifampicin, isoniazid, and pyrazinamide in the tuberculosis patients. The mean plasma concentration of rifampicin was 6.13 \xb1 4.66 microgram/ml, of isoniazid was 2.99 \xb1 1.94 microgram/ml, pyrazinamide was 38.98 \xb1 18.39 microgram/ml. There was no significant differences in the plasma concentration of rifampicin, isoniazid, and pyrazinamide in groups of pulmonary tuberculosis and pleural tuberculosis patients. Percentage of patients with plasma concentration below therapeutic concentration was 76.83% of rifampicin, 51.85% of isoniazid, 10.13% of pyrazinamide. There were 12.03% of patients who had pyrazinamide concentration higher than the therapeutic range. Conclusions: There was a wide range of plasma concentration in rifampicin, isoniazid, and pyrazinamide of tuberculosis patients. Low plasma concentration of rifampicin and isoniazid are common. It may be necessary to optimize the drug dose by therapeutic drug monitoring, especially in patients with an inadequate clinical response to chemotherapy.
tuberculosis
;
rifampicin
;
isoniazid
;
pyrazinamide
7.Recent Trend in Chemotherapy for Pulmonary Tyberculosis.
Journal of the Korean Pediatric Society 1977;20(2):83-86
Numerous problems has not been solved in the field of pulmonary tuberculosis, especially in chemotherapy. There has been many turning points in the treatment of pulmonary tuberculosis such as; introduction of streptomycin, combination therapy, isoniazid single therapy, intermittent chemotherapy, and recent short-term chemotherapy. It is very important to know about individual drugs for the better chemotherapy. So a review has been made referring many literatures in pharmacologic properties of them. Also single INH therapy, double chemotherapy and triple chemotherapy have be described.
Drug Therapy*
;
Isoniazid
;
Streptomycin
;
Tuberculosis, Pulmonary
8.The Current Status of Multidrug-resistant Tuberculosis in Korea.
Byoung Ju KIM ; In Hee LEE ; Duk Hyung LEE ; Gill Han BAI ; Suk Jun KONG ; Sun Hwa LEE ; Hae Ran MOON ; Kyoung Ryul LEE ; Jun Young LEE ; Seung Kyu PARK
Tuberculosis and Respiratory Diseases 2006;60(4):404-411
PURPOSE: Multidrug-resistant tuberculosis (MDR-TB) is an emerging threat to human beings. However, there is little data on the current status of MDR-TB in Korea. This study investigated the current status of MDR-TB in Korea using a survey of all the data from drug susceptibility tests (DST) performed across the country over the last three years. METHOD: The DST results between Jan. 2000 and Dec. 2002 from 7 laboratories, which were in charge of all antituberculous DSTs across the country as of March 2002, were collected and analyzed to determine the actual number of drug-resistant or MDR-TB patients, annual trend, degree and pattern of resistance against anti-TB drugs, etc. RESULTS: Six laboratories used the absolute concentration method for DST and one used the proportional method. 59, 940 tests had been performed over the 3 year study period. The number of DST performed annually was 18,071, 19,950, and 21,919 in 2000-2002, respectively. The number of resistant tuberculosis patients (resistant against at least one anti-TB drug) had increased by 16.9% from 6,338 in 2000 to 7,409 in 2002. The rate of resistant tuberculosis among all DST results was 35.1% in 2000, 34.5% in 2001, and 33.8% in 2002. The number of MDR-TB patients (resistant against at least both isoniazid and rifampin) showed an increasing trend (14.5%) from 3,708 in 2000 to 4,245 in 2002. CONCLUSION: Approximately 4,000 MDR-TB cases are newly identified by DST annually and the number is showing an increasing trend. This study suggests that in order to cope with the current MDR-TB situation, the DST methods will need to be standardized and more aggressive measures will be required.
Humans
;
Isoniazid
;
Korea*
;
Tuberculosis
;
Tuberculosis, Multidrug-Resistant*
9.A case report of isoniazid-associated psychosis.
Taehoon LEE ; Yongchel AHN ; Hyun Woo PARK ; Kyoungwon JUNG ; Sung Han KIM ; Yang Soo KIM ; Jung Sik PARK
Korean Journal of Medicine 2010;78(5):650-653
A 42-year-old woman without a prior psychiatric history presented with psychotic symptoms that were suspected as related to treatment of tuberculosis with isoniazid. The psychotic symptoms resolved after isoniazid was discontinued. Clinicians should be aware of the possibility of psychotic symptoms with use of this agent.
Adult
;
Female
;
Humans
;
Isoniazid
;
Psychotic Disorders
;
Tuberculosis
10.Rapid Drug Susceptibility Testing for Isoniazid and Rifampicin by Reverse Hybridization Assay.
Young Kil PARK ; Hee Kyoung YU ; Sung Weon RYU ; Gill Han BAI
Tuberculosis and Respiratory Diseases 2003;55(5):440-448
BACKGROUND: Development of rapid drug susceptibility testing provides the opportunity for rapid identification of individuals with drug resistant tubercle bacilli, allowing selection of appropriate therapeutic regimens. METHODS: A total of 502 drug resistant isolates were subjected to reverse blot hybridization assay to detect mutations within genes (rpoB, katG, inhA, and ahpC) associated with rifampicin (RMP) and isoniazid (INH) resistance. RESULTS: Among the 264 RMP resistant strains (RMPR) tested, the most prevalent mutation was the Ser531Leu seen in 121 strains (46%). The second common mutation occurred in 84 strains (32%) at codon 526. And 27 strains (10%) showed the mutation at codon 516. Among all 469 INH resistant strains (INHR), the katG mutation was responsible for INH. The inhA mutation was present in 88 strains (19%). In 11 isolates (2%), coexisting of the katG and inhA mutations were identified. Reverse hybridization assay successfully detected over 80% of INHR and over 92% of RMPR among Korean isolates. CONCLUSION: Reverse hybridization was useful for rapid detection of INHR and RMPR.
Codon
;
Genotype
;
Isoniazid*
;
Korea
;
Mycobacterium tuberculosis
;
Rifampin*